Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132193 | 0.94 | CLK1 (0.36) | CLK1DYRK1ADYRK1BPRKCICTNNB1 | |
| SCHEMBL104215 | 0.86 | — | — | |
| SCHEMBL27032744 | 0.85 | CA1 (0.31) | CA1CA9TSHR | |
| SCHEMBL910334 | 0.78 | CLK1 (0.33) | CLK1DYRK1ADYRK1BPRKCICTNNB1 | |
| SCHEMBL106413 | 0.75 | ITGB2 (0.39) | — | |
| SCHEMBL3260298 | 0.73 | LMNA (0.39) | — | |
| SCHEMBL22225 | 0.72 | TSHR (0.46) | TSHR | |
| SCHEMBL27493 | 0.71 | TSHR (0.52) | CLK1DYRK1ADYRK1BPRKCICTNNB1 | |
| SCHEMBL16340888 | 0.71 | TSHR (0.52) | CLK1DYRK1ADYRK1BPRKCICTNNB1 | |
| SCHEMBL104043 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | claimed |
| EP-2078010-B1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2014-01-29 | — | — | EP | claimed |
| US-7709482-B2 | angiogenesis and/or cell proliferation, carcinoma, myeloid leukemia, endometriosis; inhibitors of the receptor protein tyrosine kinase; N3-(3-cyclopentyl-1,2,3,4,5,6-hexahydrobenzo[d]azocin-8-yl)-1-(6-fluoroquinazolin-4-yl)-1H-1,2,4-triazole-3,5-diamine | RIGEL PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | claimed |
| EP-2078010-A2 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2009-07-15 | — | — | EP | claimed |
| US-20080188455-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | claimed |
| WO-2008083367-A2 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | claimed |
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | BERGENBIO ASA (NO) | 2023-11-23 | — | — | US | disclosed |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | BERGENBIO ASA (NO) | 2023-08-10 | — | — | US | disclosed |
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| US-20230149397-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| EP-4138823-A1 | METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR | BerGenBio ASA (NO) | 2023-03-01 | — | — | EP | disclosed |
| EP-4132652-A1 | AXL INHIBITORS FOR ANTIVIRAL THERAPY | BerGenBio ASA (NO) | 2023-02-15 | — | — | EP | disclosed |
| US-20110098274-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100196511-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100168416-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-7709482-B2 | angiogenesis and/or cell proliferation, carcinoma, myeloid leukemia, endometriosis; inhibitors of the receptor protein tyrosine kinase; N3-(3-cyclopentyl-1,2,3,4,5,6-hexahydrobenzo[d]azocin-8-yl)-1-(6-fluoroquinazolin-4-yl)-1H-1,2,4-triazole-3,5-diamine | RIGEL PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| EP-2078010-A2 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20080188455-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2008083367-A2 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196511-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | AXL, FLT3, MET | CLK1 810/4885DYRK1A 880/4885DYRK1B 707/4885 |
| US-20230149397-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | AXL, CD274, HAVCR2 | CLK1 1058/4885DYRK1A 615/4885DYRK1B 595/4885 |
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | AXL, CD274, CD47 | CLK1 1289/4885DYRK1A 790/4885DYRK1B 538/4885 |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | FLT3, AXL, SARS1 | CLK1 1836/4885DYRK1A 3431/4885DYRK1B 3236/4885 |
| US-20100168416-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | CLK1 926/4885DYRK1A 179/4885DYRK1B 195/4885 |
| US-20230159522-A1 | BCL-2 INHIBITOR | BCL2, BCL2A1, BCL2L1 | CLK1 1764/4885DYRK1A 2763/4885DYRK1B 2578/4885 |
| US-20080188455-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | CLK1 926/4885DYRK1A 179/4885DYRK1B 195/4885 |
| US-20110098274-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | CLK1 926/4885DYRK1A 179/4885DYRK1B 195/4885 |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | STK11, MERTK, AXL | CLK1 85/4885DYRK1A 281/4885DYRK1B 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.